This week, beginning on Wednesday, the Cancer Research Institute (CRI) will be teaming up with three other cancer organizations to co-host an international scientific meeting devoted to cancer immunotherapy. Entitled “Translating Science into Survival,” the meeting aims to bring together all the major stakeholders in the field for a four-day conference devoted to exploring the latest advances and problems in this rapidly evolving field.
As science writer for the Cancer Research Institute, I will be there to cover the main events of the day and will be reporting back to you in daily blog posts. The meeting promises to be chock-full of exciting new developments. Some of the sessions I am particularly excited to attend are those being hosted by luminaries in the field of checkpoint blockade therapy—like James Allison, Arlene Sharpe, and Alan Korman—as well as talks on identifying new genetic targets for “personalized immunotherapies,” and the relationship between the microbiome and cancer. I also look forward to several talks by current CRI postdoctoral fellows who were invited to speak based on their submitted abstracts.
CRI is happy to be collaborating with the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) on the meeting, which will be held at the Sheraton Times Square in New York City. This joint meeting will provide an unparalleled opportunity for teaching, learning, and networking among everyone with a stake in the future of the field.
If you don’t have a ticket already, however, you won’t be able to attend, as the meeting is currently sold out, with nearly 1,400 registered participants! But you can still learn about what takes place at the conference by checking back here on the CRI blog, and by following the conversation on social media using #CICON15.